Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies

Roxane Dilcher; Stephan Wall; Mattes Groß; Sabrina Katzdobler; Olivia Wagemann; Carla Palleis; Endy Weidinger; Urban M. Fietzek; A. Bernhardt; Carolin Kurz; Christian Ferschmann; Maximilian Scheifele; Mirlind Zaganjori; Johannes Gnörich; Katharina Bürger; Daniel Janowitz; Boris‐Stephan Rauchmann; Sophia Stöcklein; Peter Bartenstein; Victor L. Villemagne; John Seibyl; Osama Sabri; Henryk Barthel; Robert Perneczky; Florian Schöberl; Andreas Zwergal; Günter U. Höglinger; Johannes Levin; Nicolai Franzmeier; Matthias Brendel

doi:10.1002/alz.14185

Abstract

Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker-based workflows to assess 4R-tauopathy (4RT) patients are currently missing. We suggest a novel biomarker-based algorithm to characterize AD and 4RTs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dilcher et al. (2024) studied this question.

synapsesocial.com/papers/68e58a69b6db643587526a20 https://doi.org/10.1002/alz.14185

View Full Paper

Ask AI

Bookmark

Share

Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies

Abstract

Discussion

Cite This Study

Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies

Abstract

Discussion

Cite This Study

Keep reading

Keep reading